|
 It said it expected the final decision from the European Commission
in the third quarter of 2014.
In a separate statement, Bayer said the same European expert panel
at the European Medicines Agency (EMA) recommended the approval of
its eye drug Eylea for the treatment of visual impairment due to
diabetic macular oedema.
The European Commission, which rules over drug approvals in the EU,
typically follows the recommendations issued by the EMA.
(Reporting by Ludwig Burger; Editing by Kirsti Knolle)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
